Latin America moves on rimonabant and drug safety
This article was originally published in Scrip
Regulatory authorities in Latin America have responded quickly to theEMEA's recommendation last week to suspendSanofi-Aventis's obesity treatment Acomplia (rimonabant) owing to concerns over increased risk of psychiatric disorders (ScripOnline, October 24th, 2008).
You may also be interested in...
While information sharing is key to cross-country collaborations on access to medicines and can lead to major benefits, it is hard to sell to political leaders and the media, says a report from the World Health Organization’s regional office for Europe.
The European Commission says it will publish its review of the EU orphan drug legislation in the coming days.
The UK has formally withdrawn its ratification of the Unified Patent Court Agreement, adding to the uncertainty over its future.